

MSC/A/076/2021 Draft agenda 2 December 2021

# Draft Agenda

76<sup>th</sup> meeting of the Member State Committee

14-15 December 2021

(ECHA Conference Centre)

Web conference

14 December: starts at 10:00 am 15 December: ends at 1:00 pm

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

MSC/A/076/2021 For adoption

Item 3 – Declaration of specific interests to items on the Agenda

Item 4 – Administrative issues

• Outlook for MSC-77

Item 5 – Minutes of the MSC-75

Adopted minutes of MSC-75

For information

For information

Item 6 – Substance evaluation

Closed session for 6.2

1. Introduction to and preliminary discussion on draft decisions on substance evaluation when amendments were proposed by MS-CA's/ECHA (Session 1, open session):

No cases<sup>1</sup>

For discussion

2. Seeking agreement on draft decisions when amendments were proposed by MS-CA's/ECHA (Session 2, closed)

No cases

<sup>&</sup>lt;sup>1</sup> List of cases agreed in MSC Written Procedure is available in the Appendix of this document.

#### <sup>2</sup> Comments received from MSC during 30 September - 1 November are available in Interact MSC-75 under RECOM Pre-meeting folder.

#### 3. General topics

Item 7 – Dossier evaluation

1. Introduction to and preliminary discussion on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's (Session 1, open session)

For discussion followed by agreement seeking under 7.2:

**Compliance checks** 

MSC code<sup>1</sup>

CCH-179/2021	O,O,O-triphenyl phosphorothioate

Substance name

2. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (Session 2, closed)

As listed under 7.1

3. General topics

Item 8 – SVHC identification - Seeking agreement on Annex XV proposals for

identification of SVHC

Seeking agreement on Annex XV proposals for identification of SVHC

# A case stopped from MSC written procedure

Substance name <sup>1</sup>	EC/List No.	CAS No.	Documents
S-(tricyclo(5.2.1.0'2,6)deca-3-en-8(or 9)- yl O-(isopropyl or isobutyl or 2-ethylhexyl) O-(isopropyl or isobutyl or 2-ethylhexyl)	401-850-9	255881-94-8	ECHA/MSC- 76/2021/006-9
phosphorodithioate			

For agreement

Item 9 – ECHA's recommendations of priority substances to be included in Annex XIV and opinion of MSC

Presentation and discussion of 11<sup>th</sup> draft recommendation

ECHA/MSC-76/2021/004-52

Closed session for 7.2

[For information]

EC/List No./ **Documents** 209-909-9 ECHA/MSC-76/2021/002-3

ECHA/MSC-76/2021/010

For information

For discussion

### For agreement

[For information]

For agreement

Item 10 – ECHA's draft update of the Community Rolling Action Plan and opinion of MSC

#### Introduction of the draft CoRAP update by SECR

ECHA/MSC-76/2021/001

For information

1. Update on appeals and court cases of relevance to MSC

(Partly closed session) For information

For information

2. Suggestions from members

Item 12 – Adoption of summary record of the proceedings and conclusions and action points

• Table with summary record and conclusions and action points from MSC-76

For adoption

#### INFORMATION DOCUMENTS

Information documents are not allocated a specific agenda time but the documents are available on Interact MSC Meetings module before the meeting. Based on the listed documents and the meeting agenda, if any MSC member considers that information documents may merit a discussion under any agenda point, they should inform MSC Secretariat.

- Written procedure report on seeking agreement on draft decisions on substance evaluation (For members only)

- Written procedure report on seeking agreement on draft decisions on dossier evaluation (For members only)

- Written procedure report on seeking agreement on Annex XV proposals for identification of SVHC

- Approach paper on requesting the Fish sexual development test (OECD TG 234) under Compliance Check (For members only)

- Comments received on mutagenicity discussion paper: Proposal on the use of the Chromosome Aberration (CA) test under REACH both in *in vitro* and *in vivo* (Follow up to MSC-75 Item 12.3a)

# Item 11 – Any other business Partly closed session

#### APPENDIX to the MSC-76 agenda:

## List of evaluation cases agreed by MSC in written procedure in advance of the MSC-76 meeting:

#### Substance evaluation

MSC code	Substance name	EC/List No.
SEV-BE-025/2020	Perfluamine	206-420-2
SEV-NL-021/2020	Phenol, isopropylated, phosphate (3:1)	273-066-3
SEV-DE-022/2020	1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-	216-133-4 and 244-
	hexamethyl-2-naphthyl)ethan-1-one	240-6
SEV-DE-023/2020	(3E)-1,7,7-trimethyl-3-(4-	701-394-3
	methylbenzylidene)bicyclo[2.2.1]heptan-	
	2-one	

## **Dossier evaluation**

Compliance checks			
MSC code	Substance name	EC/List No.	
CCH-178/2021	N,N-diethylhydroxylamine	223-055-4	

#### Testing proposal examinations

MSC code	Substance name	EC/List No.
TPE-095/2021	1,1,1,2,2,4,5,5,5-nonafluoro-4- (trifluoromethyl)-3-pentanone	436-710-6
TPE-096/2021	1,1,1,2,2,4,5,5,5-nonafluoro-4- (trifluoromethyl)-3-pentanone	436-710-6
TPE-099/2021	N-[2-[(2-cyano-4,6-dinitrophenyl)azo]-5- (diethylamino)phenyl]acetamide	246-058-2
TPE-109/2021	3-(benzothiazol-2-yl)-7-(diethylamino)-2-oxo- 2H-1-benzopyran-4-carbonitrile	274-668-9

#### SVHC identification<sup>3</sup>

#### Substance name

EC/List No. CAS No.

-

-

(±)-1,7,7-trimethyl-3-[(4methylphenyl)methylene]bicyclo[2.2.1]heptan-2one covering any of the individual isomers and/or combinations thereof (4-MBC)

<sup>&</sup>lt;sup>3</sup> SVHC proposals for 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol (DBMC) (EC No. 204-327-1, Cas 119-47-1) and tris(2-methoxyethoxy)vinylsilane (EC No. 213-934-0, Cas 1067-53-4) were not referred to MSC but will be added to the Candidate List without MSC involvement.